Introduction
Methods
-
studies reporting on IPC
-
studies conducted in the primary care setting, involving primary care providers exclusively
-
studies involving at least 2 different primary care providers, regardless of the type and level of collaboration (from a simple phone call to a multidisciplinary medical appointment).
-
interventions involving multidisciplinary teams working between primary and secondary care
-
the absence of a primary endpoint centred on patient health (studies focusing on economic outcomes, manuscripts reporting practices for declarative data only)
-
the absence of a comparative design with a control group and statistical analysis (studies based on a before-after design involving the follow-up of only one cohort of patients were excluded)
-
abstracts not respecting the IMRAD structure
-
manuscripts not accessible in English.
Results
Selection and general description of the studies
Constitution of the teams (Table 1)
1GP + 1 other health professional | 28 |
Pharmacist | 14 |
Nurse | 10 |
Psychologist | 2 |
Health assistant | 2 |
1GP + 2 or more different health professionals | 33 |
Pharmacist | 10 |
Nurse | 27 |
Psychologist/psychiatrist | 13 |
Health assistant | 2 |
Dietician | 10 |
Social worker | 8 |
Medical specialist | 7 |
Physiotherapist | 5 |
Podiatrist | 1 |
Occupational therapist | 2 |
Pathologies
Effect on patient variables
Patients at cardiovascular risk (Tables 2 and 3)
Author year | Region | Design | Population / Pathology | Intervention | Number | Number of type of professionals | Duration |
---|---|---|---|---|---|---|---|
Agarwal 2019 [20] | North America | P / Rd | Diabetes | Diabetes education and self-management by a multi-modal training program | 50 | > 2 | < 12 months |
Barceló 2010 [21] | South America | P / Rd | Diabetes | Multidisciplinary care: professional training and diabetes education for patients | 307 | > 2 | 12—24 months |
Benedict 2018 [22] | North America | R / NRd | Diabetes | Adding clinical pharmacists to an integrated health care team | 1960 | > 2 | 12—24 months |
North America | P / Rd C | Hypertension | Physician-pharmacist co-management | 402 | 2 | < 12 months | |
Carter 2015 [25] | North America | P / Rd C | Hypertension | Physician/pharmacist collaborative model | 625 | 2 | 12—24 months |
Carter 2018 [26] | North America | P / Rd C | Cardiovascular diseases | Physician/pharmacist centralized collaborative care | 302 | 2 | 12—24 months |
Chen 2010 [27] | North America | P / NRd | Diabetes / hypertension | Health coaches visits and calls / coordination with resident primary care physicians | 146 | 2 | 12—24 months |
Choi 2015 [28] | Asia | P / NRd | Brain stroke | Secondary stroke prevention programme | 577 | 2 | 12—24 months |
Chwastiak 2017 [29] | North America | R / NRd | Diabetes | Multi-condition collaborative care: assessment, education self-management, behavioural interventions, care coordination | 634 | > 2 | 12—24 months |
Edwards 2012 [30] | North America | R/ NRd | Diabetes | Diabetes Assessment Service (DAS)/ collaboration with pharmacist | 304 | 2 | 12—24 months |
ElGerges 2020 [31] | Asia | P / Rd | Diabetes | Therapeutic patient education | 100 | > 2 | < 12 months |
Fokkens 2011 [32] | Europa | P / NRd | Diabetes | Structured care: multidisciplinary cooperation and patients + professionals education | 1001 | > 2 | > 24 months |
Furler 2017 [33] | Australia | P / Rd | Diabetes | Reconfigured role for primary care: practice nurses / interaction GPs | 266 | 2 | 12—24 months |
Heisler 2012 [34] | North America | P / Rd | Diabetes | Adherence and intensification of medications intervention by pharmacists | 4100 | 2 | > 24 months |
Jameson 2010 [35] | North America | P / Rd | Diabetes | Pharmacist management in a community-based primary care group | 103 | > 2 | 12—24 months |
Asia | P / NRd | Diabetes | Multidisciplinary risk assessment and management program | 2496 / 18188 | > 2 | > 24 months | |
Manns 2012 [38] | North America | R / NRd | Diabetes | Care managed in a primary care network | 154928 | > 2 | 12—24 months |
McAdam- Marx 2015 [39] | North America | R/ NRd | Diabetes | Clinical pharmacy services in community-based primary | 697 | > 2 | 12—24 months |
Mousquès 2010 [40] | Europa | P / NRd | Diabetes | Collaboration nurses/ physicians / patient education | 1684 | 2 | < 12 months |
Mundt 2015 [41] | North America | R/ NRd | Cardiovascular disease | Different primary care social networks, with different level of interaction | 7457 | > 2 | 12—24 months |
Pape 2011 [42] | North America | P / Rd | Diabetes | Team-based care approach with electronic medical record | 6963 | 2 | 12—24 months |
North America | P / Rd | Diabetes | Adding pharmacists to primary care team | 260 | > 2 | 12—24 months | |
Smith 2004 [45] | Europa | P / Rd | Diabetes | Education of participants practitioners, introduction of a community-based diabetes nurse specialist, protocols, and communication | 183 | > 2 | 12—24 months |
Smith 2016 [46] | North America | P / Rd | Hypertension | Physician-pharmacist collaborative mode | 169 | 2 | < 12 months |
Tahaineh 2011 [47] | Asia | P / Rd | Dyslipidaemia | Physician–pharmacist collaboration and patient education | 152 | 2 | < 12 months |
Tobari 2010 [48] | Asia | P / Rd | Hypertension | Physician–pharmacist program of cooperation | 132 | 2 | < 12 months |
Vitale 2020 [49] | North America | P / Rd | Diabetes | Teams of nurse and dietitian: self-management education | 771 | > 2 | 12—24 months |
Weber 2010 [50] | North America | P / Rd C | Hypertension | Pharmacist-physician comanagement | 175 | 2 | < 12 months |
Author year | Main Outcomes | Results | Statistics | ||
---|---|---|---|---|---|
Agarwal 2019 [20] | Self-Efficacy for Diabetes scale at 4 months | I = 7,93 C = 7,06 Difference at 4 months = 0.65 95%CI [- 0.11—1.40] | NS | ||
Barceló 2010 [21] | Percent of patients at the target | Group comparison at the end | |||
HbA1c < 7% | I = 27.6% to 39.3% C = 20.7% to 27.9% | p = 0.03 | |||
Chol-total < 200 | I = 65.1% to 76.5% C = 54.1% to 58.6% | NS | |||
BP ≤ 140/90 | I = 73.4% to 75.1% C = 72.5% to 69.3% | NS | |||
Foot examination done | I = 49.0% to 95.4% C = 46.8% to 21.6% | p < 0.01 | |||
Eye examination done | I = 10.2% to 73.0% C = 3.6% to 4.5% | p < 0.01 | |||
Three or more treatment goals | I = 16.6% to 69.7% C = 12.4% to 5.9% | p < 0.01 | |||
Benedict 2018 [22] | HbA1c < 8% at 12 months | Adj. OR = 0.88 95%CI [0.72–1.07] | NS | ||
Carter 2009 [23] Chen 2013 [24] | Improvement in guideline adherence at 6 months | I = 22.4 C = 4.0 Adj. OR = 9.6 95% CI [-2.3—21.5] | NS | ||
Nb of patient with controlled blood pressure | I = 63.9% C = 29.9% Ad. OR = 3.2 95% CI [2.0—5.1] | p < 0.001 | |||
SBP variation at 6 months | I = -20.7 C = -6.8 Ad.. effect = -12.0 95% CI [-24.0—0.0] | p < 0.05 | |||
DBP variation at 6 months | I = -9.7 C = -4.5 Ad. effect = -1.8 95% CI [-11.9—8.3] | NS | |||
Mean 24-h SBP | I = 135.6 to 120.4 C = 137.0 to 131.8 | Baseline NS / 6 months p < 0.001 | |||
Patients with controlled SBP(%) | I = 39.8 to 75.6 C = 35.4 to 50.0 | Baseline NS / 6 months p < 0.001 | |||
Carter 2015 [25] | SBP at 9 months | I = 131.6 C = 138.2 | p = 0.002 | ||
DBP at 9 months | I = 76.3 C = 78.0 | p = 0.005 | |||
Carter 2018 [26] | Evolution of Guideline Advantage Score | I = 63.3% to 67.8% (p = 0.02) C = 64.7% to 63.1% (NS) | p = 0.07 | ||
Chen 2010 [27] | Adj. p-value | ||||
LDL-C measured | I = 74.0% to 84.9% C = 56.2% to 72.9% Difference in change = -5.8% | p = 0.001 | |||
HbA1c measured | I = 86.9% to 88.9% C = 93.7% to 90.1% Difference in change = + 5.6% | NS | |||
BP (proportion of patients at goal) | I = 48.7% to 56.5% C = 41.4% to 45.4% Difference in change = + 3.8% | NS | |||
LDL-C (proportion of patients at goal) | I = 49.1% to 58.6% C = 52.5% to 58.8% Difference in change = + 3.2% | NS | |||
HbA1C (proportion of patients at goal) | I = 26.7% to 36.7% C = 25.9% to 34.8% Difference in change = + 1.8% | NS | |||
Choi 2015 [28] | New stroke | I = 2.7% C = 0.8% | NS | ||
Pré to post intervention: | |||||
SBP | I = 135.2 to 127.7 C = 135.7 to 134.5 (no difference at baseline) | I: p < 0.01 C: NS | |||
DBP | I = 70.4 to 68.1 C = 73.5 to 72.1 (difference at baseline p < 0.01) | I: p < 0.01 C: p = 0.04 | |||
HbA1c | I = 7.2 to 6.5 C = 7.2 to 6.9 (no difference at baseline) | I: p < 0.01 C: p = NS | |||
LDL-C | I = 3.4 to 2.8 C = 3.0 to 3.0 (difference at baseline p < 0.01) | I: p < 0.01 C: p = NS | |||
Ex-smoker | I = 14. % To 18.8% C = 23.3% to 27.1% (no difference at baseline) | I: p < 0.01 C: p < 0 .01 | |||
Chwastiak 2017 [29] | Change in HbA1c | ||||
Change in SBP | I = -0.9% C = -0,2% | p = 0.008 | |||
Outpatient clinic visits | I = -3 mmHg C = + 1,4 mmHG | p = 0.014 | |||
Emergency department visits | I = 14.5 C = 8.3 | p < 0.001 | |||
I = 1.8 C = 1.5 | NS | ||||
Edwards 2012 [30] | Proportion of patients with: | ||||
HbA1c measured | I = 91,2% C = 76,7% OR 3,13 95%CI [1,52–6,46] | p = 0.0013 | |||
LDL-C measured | I = 95,6% C = 70,0% OR 9,26 95%CI [3,60–23,79] | p < 0.0001 | |||
Foot exam | I = 87,6% C = 47,6% OR 7,78 95%CI [4,18–14,48] | p < 0.0001 | |||
Eye referral | I = 85,8% C = 55,2% OR 5,29 95%CI [2,88–9,72] | p < 0.0001 | |||
Pneumococcal vaccine | I = 80,5% C = 37,6% OR 7,26 95%CI [4,19–12,59] | p < 0.0001 | |||
Influenza vaccine | I = 74,3% C = 50,0% OR 2,90 95%CI [1,75–4,78] | p < 0.0001 | |||
Urine sample | I = 75,2% C = 15,7% OR 17,08 95%CI [9,66–30,21] | p < 0.0001 | |||
ElGerges 2020 [31] | HbA1c | Before: I = 8.40 C = 7.7 After: I = 6.8 C = 7.5 | Comparison I-C: before p < 0.05 after p < 0.05 | ||
SBP | Before: I = 132.0 C = 129 After: I = 125.6 C = 129.0 | Comparison I-C: before NS after NS | |||
DBP | Before: I = 81.0 C = 82.2 After: I = 76.2 C = 81.2 | Comparison I-C: before NS after p < 0.01 | |||
DMSES (Diabetes Management Self-Efficacy Scale) | Before: I = 5.02 C = 4.91 After: I = 8.28 C = 4.85 | Comparison I-C: before NS after p < 0.01 | |||
SDSCA (Summary of Diabetes Self-Care Activities) | Before: I = 2.89 C = 2.67 After: I = 4.56 C = 2.48 | Comparison I-C: before NS after p < 0.01 | |||
Fokkens 2011 [32] | Difference after 1 year | ||||
HbA1c | I = 0,2 C = 0.2 Adj. OR = 1.8 95%CI[1.03–3.14] | p < 0.05 | |||
SBP | I = -2,7 C = 1.0 Adj. OR = 1.54 95%CI [0.99–2.38] | NS | |||
DBP | I = -1,8 C = -0.4 Adj. OR = 2.13 95%CI [1.37–3.32] | p < 0.05 | |||
LDL-C | I = -0,2 C = -0.4 Adj. OR = 2.89 95%CI [1.47–5.69] | p < 0.05 | |||
Furler 2017 [33] | Change (from baseline to 12 months) in HbA1c | I = -1,3% C = -0,6% | p < 0.001 | ||
Heisler 2012 [34] | Relative change in SBP at 6 months | I =—8.9 C = -9.0 -0.18 [-0.77- 1.13] | NS | ||
Jameson 2010 [35] | HbA1C evolution | I = -1.50 C = -0.40 | NS | ||
Changes in HbA1c | I = -0,11 C = 0.10 | p < 0.01 | |||
Observed cardiovascular events | I = 1.21% C = 2.89% | p = 0.003 | |||
Predicted 10-year cardiovascular risks Framingham | I = -3.93 C = -1.87 | p < 0.01 | |||
Time to first occurrence of a major diabetes-related complication: | Hazad ratio I versus C | ||||
composite of 3 cardio-vascular diseases | 0.629 95%CI [0.554, 0.715] | < 0.001 | |||
coronary heart disease | 0.570 95%CI [0.470—0.691] | < 0.001 | |||
stroke | 0.652 95%CI [0.546—0.780] | < 0.001 | |||
heart failure | 0.598 95%CI [0.446—0.802] | 0.001 | |||
all-cause mortality | 0.363 95%CI [0.308—0.428] | < 0.001 | |||
Manns 2012 [38] | Rate of admissions to hospital or visits to emergency departments per 1000 patients/month | I = 1.58 C = 1.96 OR = 0.83 95%CI [0.64, 1.08] | p < 0.001 | ||
McAdam-Marx 2015 [39] | HbA1c at 18 months | ||||
Baseline HbA1c ≥ 7.0%: | OR ad. -0.212 CI 95% [-0.401—-0.023] | p = 0.028 | |||
Baseline HbA1c ≥ 8.0%: | OR ad. -0.381 CI 95% [-0.616 à -0.146] | p = 0.002 | |||
Mosques 2010 [40] | Realization rates for: | ||||
HbA1c | OR (Ref = control group) | p = < 0.0001 | |||
Microalbuminuria | I = 1.868 | p = < 0.0001 | |||
Funduscopy | I = 6.716 | NS | |||
Creatinemia | I = 1.207 | p = < 0.0001 | |||
ECG | I = 2.761 | p = < 0.0001 | |||
Lipid check-up | I = 2.547 | p = < 0.0001 | |||
I = 2.154 | |||||
Mundt 2015 [41] | Full Model for Team social network | ||||
Density: | Centralization | Density | Centralization | ||
BP < 130/80 mmHg | OR = 1.15 [0.99–1.34] | OR = 1.03 [0.85–1.25] | NS | NS | |
LDL-c < 100 mg/Dl | OR = 1.14 [1.00–1.31] | OR = 0.93 [0.79–1.08] | NS | NS | |
Nb of urgent care visits | OR = 0.95 [0.55- 1.66] | OR = 1.20 [0.79–1.81] | NS | NS | |
Nb of emergency department visits | OR = 0.98[0.50–1.89] | OR = 1.33 [0.83–2.13] | NS | NS | |
Nb hospital visit days | OR = 0.62 [0.50–0.77] | OR = 1.45 [1.09–1.94] | p < 0.001 | p < 0.001 | |
Pape 2011 [42] | Patient target: LDL-C < = 100 mg/dL (%) | I = 78% C = 50% | p = 0.003 | ||
LDL-c | I = 83 vs 95 | < 0.001 | |||
≥ 10% decrease in SBP at 1 year | I = 37% C = 23% OR 1.91 95% CI [1.11–3.28] | p = 0.02 | |||
> = 1 hypertensive treatment optimization | I = 42% C = 26% OR = 1.63 95% CI [1.08–2.46] | p = 0.016 | |||
Smith 2004 [45] | HbA1c | I = 7.0% C = 6.7% | NS | ||
Smith 2016 [46] | SBP 0 to 9 months | I = 149 to 132 C = 150 to 141 | Baseline NS / 9 months p = 0.036 | ||
SBP 0 to 9 months | I = 84 to 75 C = 79 to 73 | Baseline NS / 9 months NS | |||
BP control at 9 months | I = 34,2% C = 25,9% Ad. OR = 1.92 95% CI [0.33–11.2] | NS | |||
Tahaineh 2011 [47] | Percent of patients at their LDL-c target | I = 94.5% C = 71.2% | p < 0.001 | ||
Tobari 2010 [48] | variation at 6 months: | ||||
At office: | |||||
SBP | I = -2.4 C = -0.9 | NS | |||
DBP | I =—2.3 C = -3.1 | NS | |||
At home morning | |||||
SBP | I = -2.9 C = -1.2 | NS | |||
DBP | I = -3.3 C = -1.4 | p = 0.04 CI [-5.5; -0.1] | |||
BMI | I = -0.4 C = -0.0 | p = 0.008 CI [− 0.7; − 0.1] | |||
Vitale 2020 [49] | Realization of | Overall effect size in OR | |||
HbA1c | = 1.15 | NS | |||
BP | = 1.06 | NS | |||
Diabetes management visit | = 1.22 | p = 0.02 | |||
LDL-C | = 0.87 | NS | |||
Foot exam | = 1.19 | p = 0.05 | |||
Weber 2010 [50] | Change in 24-h mean ambulatory SBP and DBP (mmHg) | Reduction SBP I = -14.1 C = -5.5 | p < 0.001 | ||
Reduction DBP I = -6.8 C = -2.8 | p < 0.001 |
Elderly and/or polypathological patients (Tables 4 and 5)
Author year | Region | Design | Population / Pathology cible | Intervention | Number | Number of type of professionals | Duration |
---|---|---|---|---|---|---|---|
Aigner 2004 [51] | North America | R / Rd | Elderly people | Collaboration nurse practitioners / physicians | 203 | 2 | 12—24 months |
North America | P / Rd | Elderly people and comorbidities | Guided Care: assessment, care guide, action plan, monthly monitoring, patient and family caregivers’ education, coordination of cares | 904 | 2 | 12–24 months | |
Boult 2011 [54] | North America | P / Rd | General population | Guided Care: assessment, care guide, action plan, monthly monitoring, patient and family caregivers’ education, coordination of cares | 850 | 2 | 12—24 months |
Boyd 2010 [55] | North America | P / Rd | Elderly people and comorbidities | Guided Care: assessment, care guide, action plan, monthly monitoring, patient and family caregivers’ education, coordination of cares | 2391 | 2 | 12—24 months |
Brown 2003 [56] | Europa | P / NRd | Elderly people | Integrated health and social care | 393 | > 2 | 12—24 months |
Burns 2000 [57] | North America | P / Rd | Elderly people (veterans) | Interdisciplinary primary care team: assessment and management | 128 | > 2 | 12—24 months |
Dolovich 2019 [58] | North America | P / Rd | Elderly people | Person-centred and team-based primary care intervention, including new health care elements | 312 | > 2 | < 12 months |
Hogg 2009 [59] | North America | P / Rd | Comorbidities | Multidisciplinary team: Physicians, nurse practitioners, pharmacists | 241 | > 2 | 12—24 months |
Lenaghan 2007 [60] | Europa | P / Rd | Elderly people | Physician–pharmacist collaboration and patient education | 136 | 2 | < 12 months |
Lin, 2014 [61] | North America | P / Rd | Depression / diabetes/ coronaropathy | Patient-centred collaborative care program | 214 | > 2 | 12—24 months |
Matzke 2018 [62] | North America | P / NRd | Comorbidities | Inclusion of clinical pharmacists in this physician– pharmacist collaborative care–based patient-centred medical home model | 4960 | > 2 | 12—24 months |
Melis 2008 [63] | Europa | P / Rd PC | Elderly people | Multidisciplinary community intervention model: nurse home visits, GP inclusion | 151 | > 2 | < 12 months |
Riverin 2017 [64] | North America | R/ NRd | Elderly people and comorbidities | Multidisciplinaryy team-based primary care practice | 312377 | 2 | > 24 months |
Sellors 2003 [65] | North America | P / Rd | Elderly people | Collaboration pharmacist/physician | 889 | 2 | < 12 months |
Sommers 2000 [66] | North America | P / Rd | Elderly people | Interdisciplinary collaborative practice intervention | 543 | > 2 | 12—24 months |
Taplin 1998 [67] | North America | P / NRd | General population | Reorganization of a care team around population-based care | 1460 | > 2 | 12—24 months |
Van Lieshout 2018 [68] | Europa | P / Rd | Elderly people | Interdisciplinary multicomponent intervention program: a medication review, physical fitness, social skills, and nutrition | 290 | > 2 | 12—24 months |
Wolff 2010 [69] | North America | P / Rd | Comorbidities | Guided Care on Family caregivers: assessment, care guide, action plan, monthly monitoring, patient and family caregivers’ education, coordination of cares | 196 | 2 | 12—24 months |
Author year | Main Outcomes | Results | Statistics |
---|---|---|---|
Aigner 2004 [51] | Number of visits to the emergency department per year | I = 1.3 C = 1.1 | NS |
Number of hospital admissions per year | I = 0.6 C = 0.5 | NS | |
Completion of mandated progress visits and histories | I = 4.6 C = 4.5 | NS | |
Number of acute visits per year | I = 3.0 C = 1.2 | p < 0.0001 | |
Average number of medications | I = 6.4 C = 6.2 | NS | |
Boult 2008 [52] Leff 2009 [53] | PACIC (Patient Assessment of Chronic Illness Care) | I = 17.4 C = 8.5; Adj. OR = 2.03 [1.22; 3.39] | p = 0.006 |
Hospital admissions | I = 0.75 C = 0.96 Adj.OR = 0.83 95%CI [0.64, 1.08] | NS | |
Emergency department visits | I = 0.36 C = 0.43 Adj. OR = 0.85 95%CI [0.62, 1.18] | NS | |
Primary care physician visits | I = 9.85 C = 10.13 Adj. OR = 1.00 95%CI [0.88, 1.14] | NS | |
Boult 2011 [54] | Hospital admissions | I = 0.57 C = 0.61 Adj.effect 0.85 [0.61–1.19] | NS |
30-Day readmissions | I = 0.09 C = 0.16 Adj.effect 0.51 [0.23–1.15] | NS | |
Hospital days | I = 3.36 C = 3.90 Adj.effect 0.79 [0.53- 1.19] | NS | |
Skilled nursing facility admissions | I = 0.13 C = 0.23 Adj.effect 0.53 [0.31–0.89] | S | |
Skilled nursing facility days | I = 2.09 C = 4.09 Adj.effect 0.48 [0.28–0.84] | S | |
Emergency department visits | I = 0.37 C = 0.44 Adj.effect 0.83 [0.56–1.21] | NS | |
Primary care visits | I = 9.35 C = 8.59 Adj.effect 1.08 [0.90–1.29] | NS | |
Specialist visits | I = 0.63 C = 0.32 Adj.effect 0.93 [0.75–1.15] | NS | |
Boyd 2010 [55] | PACIC (Patient Assessment of Chronic Illness Care) | I = 3.14 C = 2.85 Adj. Effect = 0.20 [0.07, 0.33] | p = 0.002 |
Brown 2003 [56] | % People living independently at 18 months | I = 66% C = 62% | NS |
Burns 2000 [57] | Death | I = 16.7% C = 27.9% | NS |
Group difference | |||
GHP (Health perception) | 0.011 | 0.001 | |
Clinic visits | 0.877 | 0.019 | |
Hospitalizations | 0.177 | NS | |
Katz ADL (functional status) | 0.078 | NS | |
IADL (functional status) | 0.701 | 0.006 | |
CES-D (quality of life) | 0.010 | 0.003 | |
MMS | 0.212 | 0.025 | |
Dolovich 2019 [58] | Goal attainment scaling | I = 57.79 C = 58.94 Adj. Effect -1.50 95% CI [− 6.51 to 3.50] | NS |
Hogg 2009 [59] | Variation quality of care-chronic disease | I = 0.098 C = 0.008 Difference = 0.091 95%CI[0.037—0.144] | p = 0.0013 |
Variation quality of care-prevention | I = 0.126 C = -0.056 Difference = 0.181 95%CI[0.108—0.255] | p < 0.001 | |
Lenaghan 2007 [60] | Total non-elective hospital admissions within 6 months | I = 21 C = 20 | NS |
Lin, 2014 [61] | Unfavourable control at baseline / C-I at 2 years | ||
HbA1c | C-I = -0.3 Ad. Effect size = − 0.88 95%CI [− 0.99—0.38] | NS | |
LDL-C | C-I = -9.1 Ad. Effect size = − 0.93 95%CI [− 28.7- 10.5] | NS | |
SBP | C-I = -3.1 Ad. Effect size = − 0.70 95%CI [− 11.9—5.7] | NS | |
Favourable control at baseline / C-I at 2 years | |||
HbA1c | C-I = 0.27 Ad. Effect size = − 1.26 95%CI [− 0.16—0.70] | NS | |
LDL-C | C-I = 3.7 Ad. Effect size = 0.73 95%CI [− 6.2 -13.6] | NS | |
SBP | C-I = 2.1 Ad. Effect size = 0.76 95%CI [− 3.4—7.7] | NS | |
Matzke 2018 [62] | Mean reduction: | ||
HbA1c | I = 0.46 95%CI [0.33—0.58] C = 0.08 95%CI [–0.02—0.18] | p < 0.0001 | |
SBP | I = 6,28 95%CI [4.88—7.68] C = 1,05 95%CI [–0.20—2.30] | p < 0.0001 | |
DBP | I = 2,69 95%CI [1.99—3.39] C = 1,23 95%CI [0.51—1.94] | p = 0.0071 | |
LDL-C | I = 3,72 95%CI [0.88—6.57] C = 4,15 95%CI [1.66—6.64] | NS | |
Chol-total | I = 5,08 95%CI [1.67—8.49] C = 5,34 /95%CI [2.43—8.25] | NS | |
Melis 2008 [63] | GARS-3 (Groningen Activity Restriction Scale-3) | OR = -2.2 95% CI [-4.2 to 0.3] | p < 0.05 |
MOS-20 MH (Mental Health of the Medical Outcome Study) | OR = 5.8 95% CI [0.1 to 11.4] | p < 0.05 | |
Riverin 2017 [64] | Hospital readmission within 90 days after discharge | I = 136.3 C = 140.6 Ad. OR = 1.2 CI 95% [-2.1—4.5] | NS |
Sellors 2003 [65] | Daily units of medication taken | I = 8.0 C = 7.9 | NS |
Sommers 2000 [66] | Medical service utilization: | ||
Hospital admissions per patient | I = 0.18 C = -0.02 OR = 0.63 95% CI [0.41–0.96] | p = 0.03 | |
Within 60 days readmissions | I = 5.4 C = -2.0 OR = 0.26 95% CI [0.08—0.84] | p = 0.03 | |
Office visits | I = 0.5 C = -1.5 OR = 0.85 | p = 0.003 | |
Emergency department visit | I = -0.56 C = 1.2 | NS | |
Home care visits | I = 2.6 C = 1.8 | NS | |
Health status measures: | |||
Social activities count | I = -0.3 C = 0.2 95% CI [0.02–1.0] | p = 0.04 | |
Symptom scale | I = 1.0 C = -0.5 95% CI [-3.2—0.16] | p = 0.08 | |
SF-36 | I = 0.1 C = 0.0 95% CI [-0.27—0.02] | p = 0.08 | |
HAQ /GDS/ Medication count / Nutrition checklist | NS | NS | |
Taplin 1998 [67] | Differences Study/ Surrounding / GHC population | ||
Mammogram | Study group rate improved and faster | < 0.01 | |
Occult blood screening | Study group rate improved and faster | p < 0.017 | |
Warfarin testing compliance | No improvement for study group | NS | |
Eye care compliance diabetes | No improvement for study group | NS | |
Van Lieshout 2018 [68] | Activity of daily living (ADL) measured with the Katz-6 | Adj. Katz-6 score OR = 0.96 95%CI: [0.39–2.35] | NS |
Wolff 2010 [69] | At 18 months: | ||
Caregiver strain CSI score | I-C = -0.38 Adj.effect size = -0.08 95% CI [− 0.37—0.20] | NS | |
Depression CES-D score | I-C = 1.42 Adj. effect size = 0.23 95% CI [− 0.06—0.51] | NS | |
Quality of chronic care (PACIC- Aggregate quality) | I-C = 0.40 Adj. effect size = 0.47 95% CI [0.15—0.78] | p < 0.001 | |
Productivity loss (WPAI:CG) | |||
Regular activity | I-C = − 0.05 Adj. effect size = − 0.26 95% CI [− 0.74—0.22] | NS | |
Work productivity | I-C = 0.00 Adj. effect size = 0.01 95% CI [− 0.28—0.30] | NS |
Patients with symptoms of mental or physical distress (Tables 6 and 7)
Author year | Region | Design | Population / Pathology | Intervention | Number | Number of type of professionals | Duration |
---|---|---|---|---|---|---|---|
Adler 2004 [70] | North America | P / Rd | Depression | Pharmacist intervention: assessment, patient education, communication with professionals | 533 | > 2 | < 12 months |
Aragonès 2019 [71] | Europa | P / Rd | Depression and MSDs | Care managed in a primary care team and psychoeducational programme | 328 | 2 | 12—24 months |
Areán 2007 [72] | North America | P / Rd | Depression | Collaborative care: physicians / psychiatrist / specialized nurse / psychologist | 1801 | > 2 | 12—24 months |
Chan 2011 [73] | Europa | P / Rd | Anxiety and depression | Multidisciplinary team consultation | 94 | > 2 | 12—24 months |
Engel 2016 [74] | North America | P / Rd | PTSD and depression | Centrally Assisted Collaborative Telecare | 666 | > 2 | 12—24 months |
Finley 2002 [75] | North America | P / NRd | Depression | Collaborative pharmacy practice model including pharmacy specialists | 220 | 2 | < 12 months |
Finley 2003 [76] | North America | P / Rd | Depression | Collaborative care emphasizing the role of pharmacist / patient education | 125 | 2 | < 12 months |
Kolk 2004 [77] | Europa | P / Rd | Medically unexplained symptoms | Psychological intervention by a qualified therapist + Physicians | 98 | 2 | 12—24 months |
Marklund 1999 [78] | Europa | P / NRd | MSDs | Assessment, and adapted interventions / meetings occupational therapist, GP, and physiotherapist | 138 | > 2 | < 12 months |
Morgan 2013 [79] | Australia | P / Rd | Depression by diabetes or cardiopathy patients | Practice nurse and GP every 3 months: evaluation and management | 317 | > 2 | 12—24 months |
Petersen 2014 [80] | Europa | P / Rd | Depression | Collaborative care intervention with Chronic Care Model | 626 | 2 | 12—24 months |
Rollman 2005 [81] | North America | P / Rd | Anxiety | Telephone-based collaborative care | 191 | 2 | 12—24 months |
Schaefert 2013 [82] | Europa | P / Rd C | Medically unexplained symptoms | Collaborative group intervention: Professional’s training / interpersonal approach of psychodynamically based therapy | 304 | > 2 | 12—24 months |
Sherbourne, 2001 [83] | North America | P / Rd | Depression | Quality improvement (QI) interventions for depression to primary care practices | 1299 | > 2 | 12—24 months |
Simon 1998 [84] | North America | P / Rd | Depression | Patient education, on-site: mental health treatment, adjustment of antidepressant medication, behavioural activation, and monitoring of medication adherence | 156 | > 2 | < 12 months |
Author year | Main Outcomes | Results | Statistics |
---|---|---|---|
Adler 2004 [70] | Antidepressant use rates at 6 months | I = 57,5% C = 46,2% | p = 0,025 |
Modification of the Beck Depression Inventory (BDI) at 6 months | I = 17.7 C = 19.4 | NS | |
Aragonès 2019 [71] | Depression at 12 months | ||
Remission rate (HSCL-20 < 0.5) | I = 20.1% C = 11.1% OR = 2.13 95% CI [0.94—4.85] | p = 0.070 | |
Response to treatment (50% reduction HSCL-20) | I = 39.6% C = 20.7% OR = 2.74 95% CI [1.12—6.67] | p = 0.027 | |
Pain at 12 months | |||
Response to treatment (30% reduction BPI) | I = 18.7% C = 18.5% OR = 1.02 95% CI [0.46—2.26) | NS | |
Areán 2007 [72] | Patients at 12 months: | NOT POOR(NP) / POOR (P) patients | |
Use of antidepressant (%) | NP:I = 65 C = 49 Ad. OR = 2.17 95%CI [1.53—3.08] | p < 0.001 | |
Use of psychotherapy (%) | P:I = 68 C = 48 Ad. OR = 3.25 95%CI[2.14—4.96] | p < 0.001 | |
Depressive symptoms = SCL-20 | NP:I = 44 C = 16 Ad. OR = 4.33 95%CI[3.14—5.97] | p < 0.001 | |
Health-related functional impairment = General health self-ratings | P:I = 40 C = 15 Ad. OR = 4.16 95%CI[2.52—6.85] | p < 0.001 | |
NP:I = 0.95 C = 1.36 Ad. OR = –0.41 95%CI[–0.49—–0.33] | p < 0.001 | ||
P:I = 1.07 C = 1.45 Ad. OR = –0.39 95%CI[–0.50—–0.27] | p < 0.001 | ||
PCS-12 | NP:I = 3.06 C = 3.38 Ad. OR = -0.32 95%CI[–0.43—–0.21] | p < 0.001 | |
P:I = 3.40 C = 3.69 Ad. OR = -0.29 95%CI[–0.45—–0.12] | p < 0.001 | ||
NP:I = 41.74 C = 39.88 Ad. OR = 1.67 95%CI[0.78—2.55] | p < 0.001 | ||
P:I = 38.99 C = 37.76 Ad. OR = 1.46 95%CI[0.33—2.60] | p < 0.001 | ||
Chan 2011 [73] | HADS (Hospital Anxiety and Depression Scale) | ||
6 months | I = 21.5 C = 17.5 | 0.061 | |
12 months | I = 19.5 C = 17.9 | NS | |
Engel 2016 [74] | Posttraumatic Diagnostic Scale (PDS) at 12 months | I = -6.07 C = -3.54 OR 1.62 95%CI [1.08–2.43] | p = 0.02 |
Symptom Checklist Depression Scale (SCL-20) at 12 months | I = -0.56 C = -0.31 OR 1.65 95%CI [1.13–2.42] | p = 0.01 | |
Finley 2002 [75] | Medication possession ratios | I = 0.811 C = 0.659 | p < 0.005 |
Variation of the nb of primary care visits | I = -39.4% C = -12.2% | p < 0.007 | |
Finley 2003 [76] | Compliance early phase | I = 76% C = 60% OR 2.11, 95%CI [ 0.97–4.58] | p = 0.057 |
Compliance continuation phase | I = 67% C = 48% OR 2.17, 95%CI [1.04–4.51] | p = 0.038 | |
MPR (medication possession ratio) at 3 months | I = 0.92 C = 0.89 | p = 0.48 | |
MPR at 6 months | I = 0.83 C = 0.77 | p = 0.26 | |
Change of antidepressants | I = 19% C = 4% | p = 0.016 | |
Resource utilization | I = 5% C = 24% | p = 0.54 | |
Kolk 2004 [77] | Pre-test to 12 months | ||
Self-reported | I = 27,77 to 19.9 C = 25.19 to 21.00 | NS | |
unexplained symptoms | I = 22.55 to 15.39 C = 20.44 to 13.56 | NS | |
anxiety | I = 38.90 to 25.93 C = 34.56 to 23.12 | NS | |
depression | |||
Registered | I = 4.39 to 1.95 C = 2.73 to 0.87 | NS | |
unexplained symptoms | I = 1.88 to 1.20 C = 1.47 to 1.53 | NS | |
explained symptoms | I = 4.95 to 3.39 C = 3.80 to 2.93 | NS | |
nb of consultations | |||
Marklund 1999 [78] | Number of sick days | Intervention group 63.8 / control group 92.8 | 0.006 |
Morgan 2013 [79] | PHQ-9 (Ancova) | I = 14,4 to 8,7 C = 15,1 to 10,8 | p = 0,047 |
Petersen 2014 [80] | PACIC = Patient Assessment of Chronic Illness Care | I = 3.12 C = 2.86 | p = 0.019 |
Morisky patient self-report scale (Medication adherence) | I = 2.59 C = 2.65 | NS | |
Prescribed antidepressant medications | I = 60.2% C = 55.1% | NS | |
Visits to the family physician | I = 15.96 C = 14.46 | NS | |
Visits to the mental health specialists | I = 3.01 C = 0.94 | NS | |
Rollman 2005 [81] | Hamilton Anxiety Rating Scale | -3,6 [-6,4; -0,8] / effect size (95% CI): 0,38 [0,09; 0,67] | p = 0,01 |
Schaefert 2013 [82] | At 12 months quality of life: | ||
Change in PCS (physical health part of SF-36) | I = 44.56 C = 44.14 Ad. OR = 0.32 95%CI[–1.20—1.84] | NS | |
Change in MCS (mental health part of SF-36) | I = 46.59 C = 42.09 Ad. OR = 2.30 95%CI [0.34—4.26] | p = 0.0226 | |
Sherbourne, 2001 [83] | Clinical depression at 2 years (CIDI) | I (meds) = 39%, I(therapy) = 31%, C = 34% | NS |
Simon 1998 [84] | Unable to work due to illness | OR 0.60 [0.40, 0.91] | NS |
Had to change work due to illness | OR 0.80 [0.49, 1.33] | NS | |
Cut down on activities due to illness | OR 0.68 [0.46, 0.99] | S | |
Rating health fair or poor | OR 0.94 [0.68, 1.29] | NS | |
Somatic symptoms | OR 0.69 [0.48, 0.98] | S | |
Pain symptoms | OR 0.83 [0.63, 1.09] | NS | |
Missing work/school | OR 1.25 [0.52, 3.09] | NS | |
Restricting daily activities | OR 1.04 [0.20, 5.33] | NS | |
OR 1.14 [0.38, 3.40] | NS |